RESEARCH TRIANGLE PARK, N.C. - (Business Wire) PharmaLinkFHI, Inc. (PharmaLink) announced today that it has appointed Frank Santoro, MD as Chief Medical Officer. Dr. Santoro joins PharmaLink from Protherics, a UK-based biopharmaceutical company specializing in oncology and critical care products where he served as Vice President, Clinical Development and Medical Affairs. In that capacity, he provided medical oversight and clinical study management for the company
’s clinical development programs. Prior to Protherics, Dr. Santoro worked in the Contract Research Organization (CRO) industry for more than seventeen years in positions of increasing responsibility, including ClinTrials Research, Innovex, Kendle International and Covance, where he built medical and clinical capabilities to service client
’s development programs. He has extensive experience managing global operations having directed global project management, clinical monitoring, pharmacovigilence, regulatory and biometric services. During his career, Dr. Santoro has served as project physician for more than 100 domestic and international studies, and directed project team activities for numerous multi-therapeutic Phase I-IV research programs.
“We are delighted Dr. Santoro joined our team. He brings depth to our medical and safety group and to the company’s executive management team. Dr. Santoro’s experience working for global CROs and biotech companies gives him a unique skill set to address our sponsor’s outsourcing needs. He will be a tremendous asset for our company and our clients.” commented Richard Staub, President and Chief Executive Officer.
“I am delighted to join an organization that is providing such an innovative approach to clinical research,” says Dr. Santoro. “By combining strong clinical expertise with industry leading eClinical technologies, PharmaLink offers clients unparalleled confidence in their outsourcing experience. I look forward to expanding our medical service capabilities and expertise.” added Dr. Santoro.
About PharmaLinkFHI
PharmaLink is a new breed of clinical research organization managing Phase I-IV clinical trials and post-marketing programs online in real time. From protocol development through final clinical study report, PharmaLink integrates deep clinical know-how with industry leading technologies, engaging the entire clinical team with actionable intelligence for more confident decision-making and risk management.
Biopharmaceutical and device manufacturers look to PharmaLink’s proven approach to support and streamline the product development process. Reflecting its focus on quality customer service, PharmaLink has been certified by Underwriters Laboratories on meeting global quality standards (ISO 9001:2000). PharmaLink is affiliated with Durham-based Family Health International (www.fhi.org), a not for profit public health research and services organization with offices in over 40 countries. For more information on PharmaLink, visit our web site at www.pharmalinkfhi.com.
PharmaLinkFHI, Inc.
Richard Staub, 919-484-1921, x107;
Fax: 919-313-1499; rstaub@pharmalinkfhi.com
www.pharmalinkfhi.com
